| We often advocate for the acceptance of new drugs to market, the inclusion of vision care products to provincial health coverages, and our members take part in CDA [Canadian Drug Agency] surveys and sessions. | 시각 장애
> 시각 장애 | 규제 파트너십
> 규제 기관과의 협력 | Do not know | National | Sometimes | 119063928324 |
| Submissions to the provincial government and advisory briefs to the to INESSS [Institut National d'Excellence en Santé et en Services Sociaux – National Institute of Excellence in Health and Social Services]. | 시각 장애
> 황반변성 | 규제 파트너십
> 건강기술평가(HTA) 및 급여 검토에 참여 | 100,000 | Regional | Regularly | 115043530962 |
| INESSS [Institut national d'excellence en santé et en services sociaux – National Institute of Excellence in Health and Social Services]. | 신경학적
> 다발성 경화증 | 규제 파트너십
> 건강기술평가(HTA) 및 급여 검토에 참여 | 10,000 | National | Regularly | 115059223657 |
| Patient Group Evidence submissions to Canada's Drug Agency (CADTH [Canadian Agency for Drugs and Technologies in Health]), INESSS [Institut national d'excellence en santé et en services sociaux - National Institute of Excellence in Health and Social Services] and BC [British Columbia] Pharmacare. | 호흡기
> COPD | 규제 파트너십
> 건강기술평가(HTA) 및 급여 검토에 참여 | 100,000 | National | Sometimes | 119013149214 |
| Canadian Drug Agency patient submissions. INESSS [Institut national d'excellence en santé et en services sociaux] (Quebec) patient submissions. | 호흡기
> 천식 및 알레르기 | 규제 파트너십
> 건강기술평가(HTA) 및 급여 검토에 참여 | 100,000 | National | Regularly | 119021123567 |
| Canadian Drug Agency patient submissions. | 호흡기
> 천식 및 알레르기 | 규제 파트너십
> 건강기술평가(HTA) 및 급여 검토에 참여 | 100,000 | National | Regularly | 119021123567 |
| HTA [Health Technology Assessment] submissions. | 스킨
> 피부 질환: 대부분의 유형 | 규제 파트너십
> 건강기술평가(HTA) 및 급여 검토에 참여 | 100,000 | National | Regularly | 119022981107 |
| We write letters to pCPA [pan-Canadian Pharmaceutical Alliance] when necessary. We write submissions to the HCA [Health Canada Assessment] process (CDA [Canada's Drug Agency] and INESSS [National Institute for Excellence in Health and Social Services]). | 암
> 암: 혈액 | 규제 파트너십
> 건강기술평가(HTA) 및 급여 검토에 참여 | 10,000 | National | Regularly | 119031899906 |
| We do regular submissions for HTA [Health Technology Assessment] and have active relationships with government decision-makers at many levels. | 위장관
> 위장관: 대부분의 유형 | 규제 파트너십
> 건강기술평가(HTA) 및 급여 검토에 참여 | 100,000 | National | Regularly | 119037340441 |
| We do regular submissions for HTA [Health Technology Assessment]. | 위장관
> 위장관: 대부분의 유형 | 규제 파트너십
> 건강기술평가(HTA) 및 급여 검토에 참여 | 100,000 | National | Regularly | 119037340441 |
| CDA [Canada's Drug Agency] and pCPA [pan-Canadian Pharmaceutical Alliance]. | 심혈관
> 심혈관 및 심장 질환 | 규제 파트너십
> 건강기술평가(HTA) 및 급여 검토에 참여 | 10,000 | International | Sometimes | 119040619515 |
| Patient stories for CADTH [Canadian Drug and Health Technology] and INESS [Institut national d'excellence en santé et en services sociaux – National Institute of Excellence in Health and Social Services]. | 일반 건강
> 일반 건강 | 규제 파트너십
> 건강기술평가(HTA) 및 급여 검토에 참여 | 10,000 | National | Sometimes | 119042243488 |
| Through the CDA-AMC [Canadian Drug Agency – Agence des médicaments du Canada]. | 암
> 암: 피부 | 규제 파트너십
> 건강기술평가(HTA) 및 급여 검토에 참여 | 5,000 | National | Regularly | 119042855470 |
| Heal Canada represents patient interests to regulators and pricing authorities by translating lived patient experience into structured, evidence-based policy input that is directly relevant to health technology assessment (HTA [Health Technology Assessment]) and reimbursement decision-making. | 환자 권익 옹호
> 건강 활동가 | 규제 파트너십
> 건강기술평가(HTA) 및 급여 검토에 참여 | We do not communicate with patients directly | National | Sometimes | 119044376594 |
| Heal Canada represents patient interests to regulators and pricing authorities by translating lived patient experience into structured, evidence-based policy input that is directly relevant to health technology assessment (HTA) and reimbursement decision-making. This includes generating patient-reported outcomes (PROs), real-world evidence (RWE), and qualitative patient insight that articulate unmet needs, quality-of-life impact, treatment burden, access barriers, and real-world value beyond clinical endpoints. | 환자 권익 옹호
> 건강 활동가 | 규제 파트너십
> 건강기술평가(HTA) 및 급여 검토에 참여 | We do not communicate with patients directly | National | Sometimes | 119044376594 |
| Part of CDA [Canada’s Drug Agency] review process. | 호흡기
> 폐 질환 | 규제 파트너십
> 건강기술평가(HTA) 및 급여 검토에 참여 | 10,000 | Regional | Rarely | 119044465336 |
| Advocating to Canadian regulatory bodies for increased scope of coverage for mTOR [mechanistic Target of Rapamycin] inhibitors. | 희귀
> 희귀 질환: 기타 | 규제 파트너십
> 건강기술평가(HTA) 및 급여 검토에 참여 | 1,000 | National | Sometimes | 119045262810 |
| Sitting on advisory boards at HTAs [Health Technology Assessments] and providing patient feedback to the Federal Government. | 암
> 암: 유방 | 규제 파트너십
> 건강기술평가(HTA) 및 급여 검토에 참여 | 100,000 | National | Regularly | 119049015873 |
| INESSS [Institut national d'excellence en santé et en services sociaux – National Institute of Excellence in Health and Social Services], but not for pricing, only for macro-level improvements to access. | 암
> 암: 대부분의 유형 | 규제 파트너십
> 건강기술평가(HTA) 및 급여 검토에 참여 | 1,000 | Regional | Sometimes | 119050786265 |
| Submitted patient group input to Canadian Drug Agency regarding new medications for alopecia areata to public and private payers. | 스킨
> 탈모증 | 규제 파트너십
> 건강기술평가(HTA) 및 급여 검토에 참여 | 5,000 | National | Sometimes | 119050829703 |
| CDA [Canadian Drug Agency] submissions, working with each provincial formulary. | 호흡기
> 폐 섬유증 | 규제 파트너십
> 건강기술평가(HTA) 및 급여 검토에 참여 | 100,000 | National | Regularly | 119050864232 |
| Meetings with INESSS [Institut national d'excellence en santé et en services sociaux – National Institute of Excellence in Health and Social Services] and the CDA [Canadian Drug Agency – Agence des médicaments du Canada] regarding drug access issues. | 암
> 암: 혈액 | 규제 파트너십
> 건강기술평가(HTA) 및 급여 검토에 참여 | 5,000 | National | Regularly | 119050868250 |
| HTA [Health Technology Assessment] submissions for new treatments. | 암
> 암: 방광 | 규제 파트너십
> 건강기술평가(HTA) 및 급여 검토에 참여 | 10,000 | National | Sometimes | 119051388329 |
| We provide patient input to Canada's Drug Agency when they are deciding whether or not to recommend public reimbursement for new drugs. | 시각 장애
> 시각 장애 | 규제 파트너십
> 건강기술평가(HTA) 및 급여 검토에 참여 | 100,000 | National | Regularly | 119061542318 |
| We raise awareness of emerging issues relating to drug pricing to keep patients, survivors, and caregivers. We also submit on behalf of people with lived experience through the HTA [Health Technology Assessment] opportunities with CDA-AMC [Canada's Drug Agency – Agence des médicaments du Canada] and INESSS [Institut national d'excellence en santé et en services sociaux – National Institute of Excellence in Health and Social Services]. | 암
> 암: 대부분의 유형 | 규제 파트너십
> 건강기술평가(HTA) 및 급여 검토에 참여 | 1,000 | National | Regularly | 119068300611 |
| Mostly drug reimbursement approval, but that touches on pricing as well. We participate in patient group submissions that are used in those reviews. We have done this for two new drugs in the past few years. | 희귀
> 폼페병 | 규제 파트너십
> 건강기술평가(HTA) 및 급여 검토에 참여 | 100 | National | Rarely | 119070062251 |
| We submit HTA [Health Technology Assessment] submissions to Canada Drug Agency. | 호흡기
> 폐 섬유증 | 규제 파트너십
> 건강기술평가(HTA) 및 급여 검토에 참여 | 100,000 | National | Regularly | 119070095029 |
| CDA [Canadian Drug Agency – Agence des médicaments du Canada], INESSS [Institut national d'excellence en santé et en services sociaux – National Institute of Excellence in Health and Social Services]. | 암
> 암: 대장직장암 | 규제 파트너십
> 건강기술평가(HTA) 및 급여 검토에 참여 | 10,000 | National | Regularly | 119070177334 |
| Submissions to regulatory and advisory bodies including INESSS [Institut national d'excellence en santé et en services sociaux – Quebec's health technology assessment agency] and the Canadian Drug Agency (CDA [Canadian Drug Agency]) regarding access to obesity treatments and patient perspectives on care. | 일반 건강
> 비만 | 규제 파트너십
> 건강기술평가(HTA) 및 급여 검토에 참여 | 100,000 | International | Regularly | 119071517799 |
| CDA [Canada's Drug Agency] AMC [Agence des médicaments du Canada], INESSS [National Institute of Excellence in Health and Social Services]. | 일반 건강
> 비만 | 규제 파트너십
> 건강기술평가(HTA) 및 급여 검토에 참여 | 100,000 | National | Regularly | 119072155321 |
| HTA [Health Technology Assessment] assessments and reimbursement reviews. | 환자 교육
> 환자 교육 | 규제 파트너십
> 건강기술평가(HTA) 및 급여 검토에 참여 | Do not know | National | Sometimes | 119073221885 |
| We participated in a Canada Drug Agency review of COPD [Chronic Obstructive Pulmonary Disease] medication access recently. | 호흡기
> 폐 질환 | 규제 파트너십
> 건강기술평가(HTA) 및 급여 검토에 참여 | Do not know | National | Rarely | 119074014255 |
| Patient submissions to CDA [Canada's Drug Agency]. | 류마티스성
> 루푸스 | 규제 파트너십
> 건강기술평가(HTA) 및 급여 검토에 참여 | We do not communicate with patients directly | National | Regularly | 119076616920 |
| We advocate for the approval and reimbursement of medications that improve sight or prevent sight loss. | 시각 장애
> 시각 장애 | 규제 파트너십
> 건강기술평가(HTA) 및 급여 검토에 참여 | Do not know | National | Regularly | 119076796006 |
| We fully support new technologies and therapies to Health Canada. | 장애
> 장애: 기타 | 규제 파트너십
> 마케팅 허가 제출에 기여 | 5,000 | National | Regularly | 119070019511 |
| Pre-budget submissions to Federal and Provincial governments and appearance before Senate and legislature committees. | 노인
> 노인 | 규제 파트너십
> 정책 입안자/규제 기관과의 회의 참석/진행 | 100,000 | National | Regularly | 119020601606 |
| Sitting on advisory boards at HTAs [Health Technology Assessments] and providing patient feedback to the Federal Government. | 암
> 암: 유방 | 규제 파트너십
> 정책 입안자/규제 기관과의 회의 참석/진행 | 100,000 | National | Regularly | 119049015873 |
| Represent patient issues to regulators. | 희귀
> 희귀 질환: 혈액 | 규제 파트너십
> 정책 입안자/규제 기관과의 회의 참석/진행 | We do not communicate with patients directly | National | Regularly | 119078414468 |
| Patients participate in Town Halls where some of these issues are addressed. | 혈액
> 겸상 적혈구 질환 | 규제 파트너십
> 다른 의료 지지자들과 함께 | 100 | Regional | Rarely | 119026823537 |
| Submissions to regulatory and advisory bodies including INESSS [Institut national d'excellence en santé et en services sociaux – Quebec's health technology assessment agency] and the Canadian Drug Agency (CDA [Canadian Drug Agency]) regarding access to obesity treatments and patient perspectives on care. | 시각 장애
> 황반변성 | 정책 및 법률에 영향 미치기
> 의료 정책 및 법률에 영향력 행사 | 100,000 | Regional | Regularly | 115043530962 |
| We have intervened at price review boards, advocated to policymakers and government officials, been invited to national roundtables by governments and also by pharma, etc. | 노인
> 노인 | 정책 및 법률에 영향 미치기
> 의료 정책 및 법률에 영향력 행사 | 10,000 | National | Regularly | 119044669631 |
| HTA submissions, other public consultations, awareness-building. | 스킨
> 피부 질환: 대부분의 유형 | 정책 및 법률에 영향 미치기
> 공청회 및 협의에 참여하기 | 100,000 | National | Regularly | 119022981107 |
| Provincial Legislative Advocacy days yearly. | 류마티스성
> 경피증 | 정책 및 법률에 영향 미치기
> 공청회 및 협의에 참여하기 | 5,000 | National | Regularly | 119071951250 |
| Media representation and direct advocacy to provincial Members of Parliament. | 희귀
> 희귀 질환: 유전성 | 정책 및 법률에 영향 미치기
> 의회 의원 및 정치 지도자 동원 | 1,000 | Regional | Sometimes | 115035427287 |
| Pre-budget submissions to Federal and Provincial governments and appearance before Senate and legislature committees. | 노인
> 노인 | 정책 및 법률에 영향 미치기
> 의회 의원 및 정치 지도자 동원 | 100,000 | National | Regularly | 119020601606 |
| We have intervened at price review boards, advocated to policymakers and government officials, been invited to national roundtables by governments and also by pharma, etc. | 노인
> 노인 | 정책 및 법률에 영향 미치기
> 의회 의원 및 정치 지도자 동원 | 10,000 | National | Regularly | 119044669631 |
| Getting Besrem [immunotherapy used to treat polycythemia vera in adults] approved by Health Canada for emergency use. | 암
> 암: 혈액 | 정책 및 법률에 영향 미치기
> 의료 서비스의 장벽/이상 현상 해결 | 1,000 | National | Sometimes | 119022124095 |
| We advocate for the approval and reimbursement of medications that improve sight or prevent sight loss. | 시각 장애
> 시각 장애 | 정책 및 법률에 영향 미치기
> 의료 서비스의 장벽/이상 현상 해결 | Do not know | National | Regularly | 119076796006 |
| Signed letter to PCPA [Pan-Canadian Pharmaceutical Alliance] when a negotiation is taking longer than usual or when a negotiation fails. | 암
> 암: 혈액 | 가격 책정 및 affordability 옹호
> 공정한 의약품 가격 책정 옹호 | 5,000 | National | Sometimes | 119020401468 |
| ... Heal Canada engages in formal submissions, consultations, advisory processes, and collaborative stakeholder dialogues to ensure patient perspectives are embedded in pricing, reimbursement, and access frameworks—particularly where traditional cost-effectiveness models fail to capture the full human, social, and system-level value of therapies. | 환자 권익 옹호
> 건강 활동가 | 가격 책정 및 affordability 옹호
> 공정한 의약품 가격 책정 옹호 | We do not communicate with patients directly | National | Sometimes | 119044376594 |
| We rally our community when there are ASM [Anti-Seizure Medication] shortages and to support price regulations for medication for patients with epilepsy. | 신경학적
> 간질 | 가격 책정 및 affordability 옹호
> 공정한 의약품 가격 책정 옹호 | 5,000 | Local | Regularly | 119050807827 |
| We raise awareness of emerging issues relating to drug pricing to keep patients, survivors, and caregivers informed. | 암
> 암: 대부분의 유형 | 가격 책정 및 affordability 옹호
> 공정한 의약품 가격 책정 옹호 | 1,000 | National | Regularly | 119068300611 |
| I was a member of the PMRB [Patented Medicine Prices Review Board] representing the patient perspective and have written numerous submissions to the authorities about drug access and pricing. | 암
> 암: 혈액 | 가격 책정 및 affordability 옹호
> 공정한 의약품 가격 책정 옹호 | 5,000 | National | Regularly | 119068939499 |
| Mostly drug reimbursement approval, but that touches on pricing as well. | 희귀
> 폼페병 | 가격 책정 및 affordability 옹호
> 공정한 의약품 가격 책정 옹호 | 100 | National | Rarely | 119070062251 |
| Signed letter to PCPA [Pan-Canadian Pharmaceutical Alliance] when a negotiation is taking longer than usual or when a negotiation fails. | 암
> 암: 혈액 | 가격 책정 및 affordability 옹호
> 가격 검토 위원회 협상에 참여 | 5,000 | National | Sometimes | 119020401468 |
| We have submitted to the PMPRB [Patented Medicine Prices Review Board], taken part in two PPRP RFPs [Requests for Proposal], have conversations with formulary managers at provincial Ministries of Health, and the pCPA [pan-Canadian Pharmaceutical Alliance, alliance of Canada's federal, provincial, and territorial public drug plans that negotiates drug prices on behalf of public payers.]. | 면역
> 원발성 면역결핍증 | 가격 책정 및 affordability 옹호
> 가격 검토 위원회 협상에 참여 | 5,000 | National | Sometimes | 119044550257 |
| We have intervened at price review boards, advocated to policymakers and government officials, been invited to national roundtables by governments and also by pharma, etc. | 노인
> 노인 | 가격 책정 및 affordability 옹호
> 가격 검토 위원회 협상에 참여 | 10,000 | National | Regularly | 119044669631 |
| ... In the past, we have also advocated directly with the pCPA [Provincial Council for Drug Programs], which negotiates drug prices, but this is not a regular occurrence. | 시각 장애
> 시각 장애 | 가격 책정 및 affordability 옹호
> 가격 검토 위원회 협상에 참여 | 100,000 | National | Regularly | 119061542318 |
| We write letters to pCPA [pan-Canadian Pharmaceutical Alliance] when necessary. | 암
> 암: 혈액 | 가격 책정 및 affordability 옹호
> 제조업체의 판매 가격 인하 요청 | 10,000 | National | Regularly | 119031899906 |
| We have submitted to the PMPRB [Patented Medicine Prices Review Board], taken part in two PPRP RFPs [Requests for Proposal], have conversations with formulary managers at provincial Ministries of Health, and the pCPA [pan-Canadian Pharmaceutical Alliance]. | 면역
> 원발성 면역결핍증 | 가격 책정 및 affordability 옹호
> 의약품 가격/의약품 부족 현황 추적 및 모니터링 | 5,000 | National | Sometimes | 119044550257 |
| We rally our community when there are ASM [Anti-Seizure Medication] shortages and to support price regulations for medication for patients with epilepsy. | 신경학적
> 간질 | 가격 책정 및 affordability 옹호
> 의약품 가격/의약품 부족 현황 추적 및 모니터링 | 5,000 | Local | Regularly | 119050807827 |
| We raise awareness of emerging issues relating to drug pricing to keep patients, survivors, and caregivers informed. | 암
> 암: 대부분의 유형 | 가격 책정 및 affordability 옹호
> 의약품 가격/의약품 부족 현황 추적 및 모니터링 | 1,000 | National | Regularly | 119068300611 |
| Patient group submissions—not specific to pricing itself, but to approvals for coverage. | 정신 건강
> 정신 건강: 기분 장애 | 가격 책정 및 affordability 옹호
> 제품의 급여 목록/국가 처방집 등재 옹호 | 10,000 | National | Rarely | 119020492804 |
| We have submitted to the PMPRB [Patented Medicine Prices Review Board], taken part in two PPRP RFPs [Requests for Proposal], have conversations with formulary managers at provincial Ministries of Health, and the pCPA [pan-Canadian Pharmaceutical Alliance]. | 면역
> 원발성 면역결핍증 | 가격 책정 및 affordability 옹호
> 제품의 급여 목록/국가 처방집 등재 옹호 | 5,000 | National | Sometimes | 119044550257 |
| Advocacy alongside industry partners for new therapy market entry to Canada, approvals, and access through Provincial-Territorial formularies. | 신경학적
> 간질 | 가격 책정 및 affordability 옹호
> 제품의 급여 목록/국가 처방집 등재 옹호 | We do not communicate with patients directly | National | Regularly | 119045277128 |
| CDA [Canadian Drug Agency] submissions, working with each provincial formulary. | 호흡기
> 폐 섬유증 | 가격 책정 및 affordability 옹호
> 제품의 급여 목록/국가 처방집 등재 옹호 | 100,000 | National | Regularly | 119050864232 |
| We often advocate for the acceptance of new drugs to market, the inclusion of vision care products to provincial health coverages, and our members take part in CDA [Canadian Drug Agency] surveys and sessions often. | 시각 장애
> 시각 장애 | 가격 책정 및 affordability 옹호
> 제품의 급여 목록/국가 처방집 등재 옹호 | Do not know | National | Sometimes | 119063928324 |
| Mostly drug reimbursement approval, but that touches on pricing as well. | 희귀
> 폼페병 | 가격 책정 및 affordability 옹호
> 제품의 급여 목록/국가 처방집 등재 옹호 | 100 | National | Rarely | 119070062251 |
| HTA submissions, other public consultations, awareness-building. | 스킨
> 피부 질환: 대부분의 유형 | 가격 책정 및 affordability 옹호
> 인식 제고 캠페인 참여 | 100,000 | National | Regularly | 119022981107 |
| Getting Besrem [mmunotherapy used to treat polycythemia vera in adults] approved by Health Canada for emergency use. | 암
> 암: 혈액 | 접근 경로 개선
> 의약품/의료서비스에 대한 공평한 접근 촉진 | 1,000 | National | Sometimes | 119022124095 |
| We don't provide information for drug pricing, just advocacy for drug approvals or access. | 류마티스성
> 루푸스 | 접근 경로 개선
> 의약품/의료서비스에 대한 공평한 접근 촉진 | 5,000 | Regional | No | 119022371395 |
| ... Heal Canada engages in formal submissions, consultations, advisory processes, and collaborative stakeholder dialogues to ensure patient perspectives are embedded in pricing, reimbursement, and access frameworks—particularly where traditional cost-effectiveness models fail to capture the full human, social, and system-level value of therapies. | 환자 권익 옹호
> 건강 활동가 | 접근 경로 개선
> 의약품/의료서비스에 대한 공평한 접근 촉진 | We do not communicate with patients directly | National | Sometimes | 119044376594 |
| Advocating to Canadian regulatory bodies for increased scope of coverage for mTOR [mechanistic Target of Rapamycin] inhibitors [a form of anti-cancer treatment]. | 희귀
> 희귀 질환: 기타 | 접근 경로 개선
> 의약품/의료서비스에 대한 공평한 접근 촉진 | 1,000 | National | Sometimes | 119045262810 |
| Advocacy alongside industry partners for new therapy market entry to Canada, approvals, and access. | 신경학적
> 간질 | 접근 경로 개선
> 의약품/의료서비스에 대한 공평한 접근 촉진 | We do not communicate with patients directly | National | Regularly | 119045277128 |
| INESSS [Institut national d'excellence en santé et en services sociaux – National Institute of Excellence in Health and Social Services], but not for pricing, only for macro-level improvements to access. | 암
> 암: 대부분의 유형 | 접근 경로 개선
> 의약품/의료서비스에 대한 공평한 접근 촉진 | 1,000 | Regional | Sometimes | 119050786265 |
| Meetings with INESSS [Institut national d'excellence en santé et en services sociaux – National Institute of Excellence in Health and Social Services] and the CDA [Canadian Drug Agency – Agence des médicaments du Canada] regarding drug access issues. | 암
> 암: 혈액 | 접근 경로 개선
> 의약품/의료서비스에 대한 공평한 접근 촉진 | 5,000 | National | Regularly | 119050868250 |
| We frequently advocate for the approval of new drugs for market access. | 시각 장애
> 시각 장애 | 접근 경로 개선
> 의약품/의료서비스에 대한 공평한 접근 촉진 | Do not know | National | Sometimes | 119063928324 |
| … and have written numerous submissions to the authorities about drug access and pricing. | 암
> 암: 혈액 | 접근 경로 개선
> 의약품/의료서비스에 대한 공평한 접근 촉진 | 5,000 | National | Regularly | 119068939499 |
| Submissions to regulatory and advisory bodies including INESSS [Institut national d'excellence en santé et en services sociaux – Quebec's health technology assessment agency] and the Canadian Drug Agency (CDA [Canadian Drug Agency]) regarding access to obesity treatments and patient perspectives on care. | 일반 건강
> 비만 | 접근 경로 개선
> 의약품/의료서비스에 대한 공평한 접근 촉진 | 100,000 | International | Regularly | 119071517799 |
| Patient submissions to CDA [Canada's Drug Agency]. Ongoing national advocacy for equitable access to care and treatment. | 류마티스성
> 루푸스 | 접근 경로 개선
> 의약품/의료서비스에 대한 공평한 접근 촉진 | We do not communicate with patients directly | National | Regularly | 119076616920 |
| We often focus on vaccines, but not only those. We have intervened at price review boards, advocated to policymakers and government officials, been invited to national roundtables by governments and also by pharma, etc. | 노인
> 노인 | 접근 경로 개선
> 더 넓은 백신 접근성을 위해 옹호하기 | 10,000 | National | Regularly | 119044669631 |
| We provide patient input to CDA [Canada Drug Agency] when they are deciding whether or not to recommend public reimbursement for new drugs. We also provide input to provinces. | 시각 장애
> 시각 장애 | 접근 경로 개선
> 접근성 및 관리의 불균형 해소 | 100,000 | National | Regularly | 119061542318 |
| There are not many new treatments for rare cancers, but when a new treatment or class is introduced, we act as Canada's advocacy group on behalf of sarcoma cancer patients. | 암
> 암: 육종 | 접근 경로 개선
> 희귀/초희귀 치료제 접근성 개선 | 5,000 | National | Regularly | 119078449674 |
| Heal Canada represents patient interests to regulators and pricing authorities by translating lived patient experience into structured, evidence-based policy input that is directly relevant to health technology assessment (HTA [Health Technology Assessment]) and reimbursement decision-making. | 환자 권익 옹호
> 건강 활동가 | 근거 기반 환자 의견
> 환자 인사이트를 활용하여 의사 결정에 반영하세요 | We do not communicate with patients directly | National | Sometimes | 119044376594 |
| Submitted patient group input to Canadian Drug Agency regarding new medications for alopecia areata to public and private payers. | 스킨
> 탈모증 | 근거 기반 환자 의견
> 환자 인사이트를 활용하여 의사 결정에 반영하세요 | 5,000 | National | Sometimes | 119050829703 |
| Mostly drug reimbursement approval, but that touches on pricing as well. We participate in patient group submissions that are used in those reviews. We have done this for two new drugs in the past few years. | 희귀
> 폼페병 | 근거 기반 환자 의견
> 환자 인사이트를 활용하여 의사 결정에 반영하세요 | 100 | National | Rarely | 119070062251 |
| Submissions to regulatory and advisory bodies including INESSS [Institut national d'excellence en santé et en services sociaux – Quebec's health technology assessment agency] and the Canadian Drug Agency (CDA [Canadian Drug Agency]) regarding access to obesity treatments and patient perspectives on care. | 일반 건강
> 비만 | 근거 기반 환자 의견
> 환자 인사이트를 활용하여 의사 결정에 반영하세요 | 100,000 | International | Regularly | 119071517799 |
| Heal Canada represents patient interests to regulators and pricing authorities by translating lived patient experience into structured, evidence-based policy input that is directly relevant to health technology assessment (HTA) and reimbursement decision-making. This includes generating patient-reported outcomes (PROs), real-world evidence (RWE), and qualitative patient insight that articulate unmet needs, quality-of-life impact, treatment burden, access barriers, and real-world value beyond clinical endpoints. | 환자 권익 옹호
> 건강 활동가 | 근거 기반 환자 의견
> 규제 기관에 실제 근거(RWE) 제공 | We do not communicate with patients directly | National | Sometimes | 119044376594 |
| The lived experiences of patients are at the centre of Lupus Canada's work. | 류마티스성
> 루푸스 | 근거 기반 환자 의견
> 환자 이야기와 실제 경험 서사 활용 | Do not know | National | Regularly | 119041443233 |
| Patient stories for CADTH [Canadian Drug and Health Technology] and INESS [Institut national d'excellence en santé et en services sociaux – National Institute of Excellence in Health and Social Services]. | 일반 건강
> 일반 건강 | 근거 기반 환자 의견
> 환자 이야기와 실제 경험 서사 활용 | 10,000 | National | Sometimes | 119042243488 |
| Heal Canada represents patient interests to regulators and pricing authorities by translating lived patient experience into structured, evidence-based policy input that is directly relevant to health technology assessment (HTA) and reimbursement decision-making. This includes generating patient-reported outcomes (PROs), real-world evidence (RWE), and qualitative patient insight that articulate unmet needs, quality-of-life impact, treatment burden, access barriers, and real-world value beyond clinical endpoints. | 환자 권익 옹호
> 건강 활동가 | 근거 기반 환자 의견
> 환자 이야기와 실제 경험 서사 활용 | We do not communicate with patients directly | National | Sometimes | 119044376594 |
| We also submit on behalf of people with lived experience through the Health Technology Assessment opportunities with CAD-AMC [Canada's Drug Agency / l'Agence des médicaments du Canada (CDA-AMC)] and INESSS [Institut national d'excellence en santé et en services sociaux -National Institute of Excellence in Health and Social Services]. | 암
> 암: 대부분의 유형 | 근거 기반 환자 의견
> 환자 이야기와 실제 경험 서사 활용 | 1,000 | National | Regularly | 119068300611 |
| We raise awareness of emerging issues relating to drug pricing to keep patients, survivors, and caregivers. We also submit on behalf of people with lived experience through the HTA [Health Technology Assessment] opportunities with CDA-AMC [Canada's Drug Agency – Agence des médicaments du Canada] and INESSS [Institut national d'excellence en santé et en services sociaux – National Institute of Excellence in Health and Social Services]. | 암
> 암: 대부분의 유형 | 근거 기반 환자 의견
> 환자 이야기와 실제 경험 서사 활용 | 1,000 | National | Regularly | 119068300611 |
| Heal Canada represents patient interests to regulators and pricing authorities by translating lived patient experience into structured, evidence-based policy input that is directly relevant to health technology assessment (HTA) and reimbursement decision-making. This includes generating patient-reported outcomes (PROs), real-world evidence (RWE), and qualitative patient insight that articulate unmet needs, quality-of-life impact, treatment burden, access barriers, and real-world value beyond clinical endpoints. | 환자 권익 옹호
> 건강 활동가 | 근거 기반 환자 의견
> 데이터 생성을 위한 설문조사/연구 수행 | We do not communicate with patients directly | National | Sometimes | 119044376594 |
| We often advocate for the acceptance of new drugs to market, the inclusion of vision care products to provincial health coverages, and our members regularly participate in CDA [Canadian Drug Agency] surveys and sessions. | 시각 장애
> 시각 장애 | 근거 기반 환자 의견
> 데이터 생성을 위한 설문조사/연구 수행 | Do not know | National | Sometimes | 119063928324 |
| Representation, rights advocacy, and immigration support. | HIV
> HIV 및 성 건강 | 기관 거버넌스
> 정부 자문 기구 내 대표성 확보 | 100 | National | Regularly | 115032094015 |
| We do regular submissions for HTA [Health Technology Assessment] and have active relationships with government decision-makers at many levels. | 위장관
> 위장관: 대부분의 유형 | 기관 거버넌스
> 정부 자문 기구 내 대표성 확보 | 100,000 | National | Regularly | 119037340441 |
| ... been invited to national roundtables by governments and also by pharma, etc. | 노인
> 노인 | 기관 거버넌스
> 정부 자문 기구 내 대표성 확보 | 10,000 | National | Regularly | 119044669631 |
| I was a member of the PMRB [Patented Medicine Prices Review Board] representing the patient perspective. | 암
> 암: 혈액 | 기관 거버넌스
> 정부 자문 기구 내 대표성 확보 | 5,000 | National | Regularly | 119068939499 |
| There are not many new treatments for rare cancers, but when a new treatment or class is introduced, We act as Canada's advocacy group on behalf of sarcoma cancer patientsw | 암
> 암: 육종 | 기관 거버넌스
> 정부 자문 기구 내 대표성 확보 | 5,000 | National | Regularly | 119078449674 |
| Advocacy alongside industry partners for new therapy market entry to Canada, approvals, and access. | 신경학적
> 간질 | 기관 거버넌스
> 다중 이해관계자 네트워크 내에서 효과적으로 협력하기 | We do not communicate with patients directly | National | Regularly | 119045277128 |
| Representation, rights advocacy, and immigration support. | HIV
> HIV 및 성 건강 | 환자 권리 보호/삶의 질 향상
> 환자 경험 보호/개선 | 100 | National | Regularly | 115032094015 |
| We are a peer-led organization that advocates for one another on patients' rights, on care and treatment. | HIV
> HIV | 환자 권리 보호/삶의 질 향상
> 환자 경험 보호/개선 | 1,000 | Local | Regularly | 119045557717 |
상호작용
활동 및 옹호
36 멘션
